Literature DB >> 2738604

Subcutaneous apomorphine in Parkinson's disease.

P Pollak, A S Champay, M Hommel, J E Perret, A L Benabid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2738604      PMCID： PMC1032319          DOI： 10.1136/jnnp.52.4.544

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

2.  Apomorphine infusion for motor fluctuations in Parkinson's disease.

Authors:  J A Obeso; F Grandas; J Vaamonde; M Rosario Luguin; J M Martínez-Lage
Journal:  Lancet       Date:  1987-06-13       Impact factor: 79.321

3.  Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

Authors:  G C Cotzias; P S Papavasiliou; E S Tolosa; J S Mendez; M Bell-Midura
Journal:  N Engl J Med       Date:  1976-03-11       Impact factor: 91.245

4.  Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.

Authors:  Y Agid; P Pollak; A M Bonnet; J L Signoret; F Lhermitte
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321
  4 in total
  12 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  The modern management of Parkinson's disease.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

3.  Comparison of motor response to apomorphine and levodopa in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

4.  Sublingual apomorphine and Parkinson's disease.

Authors:  A J Lees; J L Montastruc; N Turjanski; O Rascol; B Kleedorfer; H Peyro Saint-Paul; G M Stern; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

5.  Subcutaneous apomorphine in the treatment of Parkinson's disease.

Authors:  J P Frankel; A J Lees; P A Kempster; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

6.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

Review 7.  Advanced stages of PD: interventional therapies and related patient-centered care.

Authors:  Rejko Krüger; Rüdiger Hilker; Christian Winkler; Michael Lorrain; Matthias Hahne; Christoph Redecker; Paul Lingor; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2015-07-03       Impact factor: 3.575

8.  Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.

Authors:  R van der Geest; T van Laar; J M Gubbens-Stibbe; H E Boddé; M Danhof
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

9.  Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

Authors:  L Ostergaard; L Werdelin; P Odin; O Lindvall; E Dupont; P B Christensen; E Boisen; N B Jensen; S H Ingwersen; M Schmiegelow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

10.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.